Pfizer's Xalkori rides on in first-line NSCLC
This article was originally published in Scrip
Executive Summary
Pfizer is now poised to tout its anaplastic lymphoma kinase (ALK) inhibitor Xalkori (crizotinib) as a standard of care in both the first and second-line setting for patients with ALK-positive advanced non-small-cell lung cancer (NSCLC), following positive results in the Phase III PROFILE 1014 study.
You may also be interested in...
Novartis’ Zykadia ASCEND-4 Study Close But No Cigar In NSCLC
The presentation of the full data from Novartis’ ASCEND-4 study of Zykadia show decent efficacy in first-line NSCLC but are unlikely to be enough to overcome doctors’ caution over its tolerability profile, especially with rival Alecensa snapping at its heels.
NICE Backs Pfizer’s Xalkori In Lung Cancer After Firm Cuts Price (Again)
Pfizer’s oral therapy Xalkori (criotinib) for ALK-positive non-small cell lung cancer wins backing by the UK HTA after drug maker offers bigger discount than previously made and more supporting data.
The Shifting Sands Of Biopharma R&D
A year is a long time in biopharma. Pharmaprojects’ annual pipeline review finds changes in the therapeutic spread of drug candidates and a reordering of the top R&D companies, as Chinese firms made their presence felt all the more over the past 12 months.